Affiliations 

  • 1 Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan 173229, India
  • 2 Swami Keshvanand Institute of Pharmacy, Jaipur 302025, India
  • 3 Department of Chemistry, College of Natural Sciences, Yeungnam University, Gyeongsan, Gyeongbuk 38541, South Korea
  • 4 Department of Chemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, India
  • 5 Department of Pharmacy, Regional Institute of Paramedical and Nursing Sciences, Zemabawk, Aizawl, Mizoram 796017, India
  • 6 Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur 844102, India
  • 7 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, India
  • 8 Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia
  • 9 Department of Pharmacology, School of Pharmacy, Suresh Gyan Vihar University, Jaipur 302017, India
  • 10 Department of Chemistry, University of Petroleum & Energy Studies, Dehradun 248007, India
  • 11 Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology, Sydney, Ultimo-NSW 2007, Australia
ACS Omega, 2023 Jan 10;8(1):10-41.
PMID: 36643475 DOI: 10.1021/acsomega.2c04078

Abstract

Carcinoma of the lungs is among the most menacing forms of malignancy and has a poor prognosis, with a low overall survival rate due to delayed detection and ineffectiveness of conventional therapy. Therefore, drug delivery strategies that may overcome undesired damage to healthy cells, boost therapeutic efficacy, and act as imaging tools are currently gaining much attention. Advances in material science have resulted in unique nanoscale-based theranostic agents, which provide renewed hope for patients suffering from lung cancer. Nanotechnology has vastly modified and upgraded the existing techniques, focusing primarily on increasing bioavailability and stability of anti-cancer drugs. Nanocarrier-based imaging systems as theranostic tools in the treatment of lung carcinoma have proven to possess considerable benefits, such as early detection and targeted therapeutic delivery for effectively treating lung cancer. Several variants of nano-drug delivery agents have been successfully studied for therapeutic applications, such as liposomes, dendrimers, polymeric nanoparticles, nanoemulsions, carbon nanotubes, gold nanoparticles, magnetic nanoparticles, solid lipid nanoparticles, hydrogels, and micelles. In this Review, we present a comprehensive outline on the various types of overexpressed receptors in lung cancer, as well as the various targeting approaches of nanoparticles.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.